2026 Medicare CGM Coverage: New Rules & Eligibility

The 2026 Medicare CGM coverage has expanded to include beneficiaries at risk of hypoglycemia, even without insulin use, under new Local Coverage Determinations. To qualify for Medicare CGM coverage in 2026, beneficiaries must meet criteria focusing on medical necessity for diabetes management, ensuring that these life-saving tools are accessible as Durable Medical Equipment for a broader range of patients than ever before.

2026 Eligibility Expansion: Beyond Insulin

For years, the path to obtaining a continuous glucose monitor through Medicare was narrow, often reserved strictly for those requiring intensive insulin therapy. However, the landscape of Medicare CGM coverage is shifting toward a more preventative and inclusive model. This shift is largely driven by a 2023 expansion that was projected to grant eligibility to an estimated 1.5 to 2 million additional beneficiaries by removing the strict requirement for multiple daily insulin injections.

Under the Medicare CGM eligibility 2026 expansion rules, the focus has moved toward identifying medical necessity through the lens of hypoglycemia risk. This includes individuals who experience hypoglycemia unawareness or those who have had at least one level 2 hypoglycemic event (glucose levels below 54 mg/dL). For many, this means they no longer need to be on an intensive insulin regimen to access the technology needed for safe Type 2 diabetes management.

Clinical thresholds remain a vital part of the conversation. Generally, a diagnosis of diabetes is the baseline, but the 2026 rules emphasize the importance of consistent monitoring. Healthcare providers must document that the patient is meeting with them regularly—typically every six months—to assess how the CGM data is improving their treatment plan. This evolution reflects a growing understanding that real-time glucose alerts are just as critical for preventing dangerous lows as they are for managing high blood sugar.

Preferred Brands & Device Tiering in 2026

When navigating Medicare Part B glucose monitor benefits, it is important to understand that not all devices are treated equally. CMS guidelines categorize these monitors as therapeutic CGMs, meaning they are used to make treatment decisions without the constant need for fingersticks. For 2026, the primary preferred brands remain Dexcom and Abbott’s FreeStyle Libre series.

Medicare tends to favor non-adjunctive systems, which are devices cleared by the FDA to replace traditional blood glucose monitors for treatment decisions. This tiering means that if you are looking for Dexcom G7 vs Freestyle Libre 3 Medicare coverage 2026, you will find both are widely supported, but they may have different quantity limits based on their design.

For those interested in non-preferred brands, such as the Medtronic Guardian or the newer Simplera system, Medicare often employs step therapy protocols. This requires a patient to try and "fail" on a preferred brand first, or for a doctor to provide a rigorous justification as to why the preferred options are not clinically appropriate. This ensures that the program, which saw expenditures for CGMs grow from $109 million in 2018 to $1.3 billion in 2023, remains financially sustainable while providing high-quality care.

Major Shifts in Medicare Advantage (Part C)

Perhaps the most significant milestone for beneficiaries in the coming year is the regulatory update taking effect on March 1, 2026. For those enrolled in Medicare Advantage Part C, the burden of paperwork is about to lighten. A new mandate requires the removal of prior authorization requirements for many continuous glucose monitors, including the implantable CGM Medicare Advantage coverage changes 2026.

Historically, private plans under Medicare Advantage could require extensive pre-approval before a patient could pick up their sensors. By removing these hurdles, CMS aims to align private plan access with traditional Medicare. This change is particularly impactful for those who prefer to get their supplies through a retail pharmacy rather than a specialized medical equipment supplier.

Transition Timeline: Medicare Advantage

• October 2025: Many plans began a voluntary rollout of pharmacy-based CGM access.
• January 1, 2026: New annual plan cycles begin with updated cost-sharing structures.
• March 1, 2026: Mandatory removal of prior authorization for standard CGMs and implantable I-CGMs in most Medicare Advantage networks.

This shift has already begun to show results in the data. The adoption of CGMs among Medicare Advantage beneficiaries with type 2 diabetes who use insulin increased from 1.4% in January 2021 to 17.2% by December 2023. As these barriers continue to fall in 2026, that number is expected to climb even higher, making the technology a standard part of chronic care.

Supply Planning: Quantity Limits & Costs

Understanding the out of pocket costs for Medicare CGM 2026 requires a look at both Medicare Part B and Part D. Most standard CGMs are covered under Part B as Durable Medical Equipment. Under this benefit, after you meet your annual deductible, Medicare typically pays 80% of the approved amount, and you or your supplemental insurance pay the remaining 20%.

However, if you receive your CGM through a Medicare Advantage plan or a Part D prescription drug plan, you will benefit from the new $2,100 annual out-of-pocket cap on covered drugs and supplies. This provides a much-needed safety net for seniors who rely on multiple daily medications in addition to their glucose monitoring supplies.

Regarding Medicare Part B quantity limits for CGM sensors 2026, the rules are strict but generally sufficient for continuous use:

• Sensors: Medicare allows for a "continuous" supply. For a 10-day sensor like the Dexcom G7, this means 3 sensors per 30-day period. For a 14-day sensor like the FreeStyle Libre 3, it means 2 sensors per 28-day period.
• Receivers: Medicare will generally only pay for one dedicated receiver or reader every five years (365 days for certain specific plan updates), as most users now prefer to use a smartphone app to monitor their interstitial fluid glucose.
• Transmitters: For systems that use a separate transmitter (like the Dexcom G6), Medicare covers one every 90 days.

Prescriber Checklist: Documentation for Approval

Knowing how to qualify for Medicare CGM is only half the battle; the other half is ensuring your doctor uses the correct language in your medical record. Medicare is highly specific about the HCPCS billing codes and modifiers required for a claim to be paid. If the documentation is missing even one small detail, the claim may be denied.

Essential Eligibility Checklist

• Diagnosis Code: An appropriate ICD-10 code (such as E11.9 for Type 2 diabetes without complications) must be present.
• HbA1c Levels: While not the only factor, a recent A1c test (usually within the last six months) helps establish the baseline for medical necessity.
• Hypoglycemia Log: Documentation of glucose management indicator data or a log showing frequent testing and hypoglycemia risk.
• Billing Modifiers:
  • KX Modifier: Used for patients who are treated with insulin.
  • KS Modifier: Used for patients who are not treated with insulin but still meet the medical necessity criteria.

Your healthcare provider must confirm that the patient (or their caregiver) has received adequate training on how to use the device. Furthermore, the doctor must see the patient in person or via a qualified telehealth visit every six months to document that the CGM is helping the patient achieve their glycemic goals. If you are wondering how to qualify for Medicare CGM without insulin, these recurring visits and the KS modifier are the keys to maintaining your coverage.

FAQ

Does Medicare cover continuous glucose monitors?

Yes, Medicare covers therapeutic continuous glucose monitors (CGMs) under Part B as Durable Medical Equipment (DME) for beneficiaries who meet specific clinical criteria, primarily a diagnosis of diabetes and a documented need for frequent glucose monitoring.

What are the eligibility requirements for Medicare CGM coverage?

To qualify, a beneficiary must have a diabetes diagnosis, receive regular visits from a healthcare provider (every six months), and demonstrate a medical necessity for frequent monitoring. In 2026, this includes those using insulin and those at high risk for hypoglycemia, regardless of insulin use.

Does Medicare cover CGMs for Type 2 diabetes?

Yes, Medicare covers CGMs for individuals with Type 2 diabetes. While previously focused only on those using insulin, the coverage now extends to Type 2 patients who have a history of problematic hypoglycemia or who require intensive monitoring to manage their condition.

Do I need to be on insulin to qualify for a CGM under Medicare?

No, being on insulin is no longer a strict requirement for Medicare CGM coverage. Under the updated 2026 rules, patients who are not on insulin but have documented "hypoglycemia unawareness" or frequent low blood sugar events can qualify for coverage using the KS billing modifier.

How much does a CGM cost with Medicare?

Under Medicare Part B, you typically pay 20% of the Medicare-approved amount after meeting your annual Part B deductible. If you have a Medigap policy, that 20% may be covered. For those in Medicare Advantage or Part D, costs vary by plan but are subject to a $2,100 annual out-of-pocket cap for 2026.

Does Medicare Part B or Part D cover CGM supplies?

CGM supplies are primarily covered under Medicare Part B as Durable Medical Equipment. However, some Medicare Advantage and Part D plans may offer coverage through their pharmacy benefits, which can sometimes provide lower up-front costs and the convenience of picking up supplies at a local pharmacy.